Syros to Participate in Upcoming Investor Conferences in March

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) announces CEO Nancy Simonian, M.D., will participate in two investor conferences in March. The first is the Cowen 43rd Annual Health Care Conference on March 7 at 9:10 a.m. ET in Boston, focusing on Novel Oncology Targets. The second event is the Oppenheimer 32nd Annual Healthcare Conference on March 13 at 8:00 a.m. ET, conducted virtually. Syros is advancing treatments for hematologic malignancies through its clinical programs, including tamibarotene and SY-2101. For more details, visit www.syros.com.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming investor conferences in March. Management will also be available for one-on-one meetings. Details are as follows:

Cowen 43rd Annual Health Care Conference
Date: Tuesday, March 7
Panel Title: Novel Oncology Targets
Panel Time: 9:10 a.m. ET
Location: Boston Marriott Copley Place, 110 Huntington Ave, Boston, MA

Oppenheimer 32nd Annual Healthcare Conference
Date: Monday, March 13
Presentation Time: 8:00 a.m. ET
Location: Virtual

To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is advancing a robust late-stage clinical pipeline, including tamibarotene, a first-in-class oral selective RARα agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression, and SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia. Syros is also seeking partnerships for SY-5609, a highly selective and potent CDK7 inhibitor in clinical development for the treatment of select solid tumors, and multiple preclinical programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005027/en/

Syros Contact

Karen Hunady

Director of Corporate Communications & Investor Relations

1-857-327-7321

khunady@syros.com



Media Contact

Brittany Leigh, Ph.D.

LifeSci Communications, LLC

+1-813-767-7801

bleigh@lifescicomms.com



Investor Contact

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

What are the dates of the upcoming investor conferences for Syros Pharmaceuticals in March 2023?

Syros Pharmaceuticals will participate in two investor conferences in March 2023: The Cowen 43rd Annual Health Care Conference on March 7 and the Oppenheimer 32nd Annual Healthcare Conference on March 13.

What is the focus of the Cowen 43rd Annual Health Care Conference panel that Syros Pharmaceuticals will participate in?

The focus of the Cowen 43rd Annual Health Care Conference is 'Novel Oncology Targets'.

What time will Syros Pharmaceuticals present at the Oppenheimer 32nd Annual Healthcare Conference?

Syros Pharmaceuticals will present at the Oppenheimer 32nd Annual Healthcare Conference on March 13 at 8:00 a.m. ET.

How can I access the webcasts of Syros Pharmaceuticals' presentations?

You can access the webcasts and subsequent archived recordings of Syros Pharmaceuticals' presentations by visiting the Investors & Media section of their website at www.syros.com.

What are the key products in Syros Pharmaceuticals' pipeline for treating hematologic malignancies?

Key products in Syros Pharmaceuticals' pipeline include tamibarotene, a selective RARα agonist, and SY-2101, an oral form of arsenic trioxide, targeting hematologic malignancies.